WASHINGTON – Immunosyn Corp.'s statements in public filings over the past few years have landed the biotech, its shareholders and senior executives on the wrong side of the SEC. Read More
Somaxon Pharmaceuticals Inc. continued to slog through the crowded insomnia market with Silenor (doxepin) during the second quarter, growing net sales to $6.2 million – a 170 percent increase over the $2.3 million sold last quarter, and ahead of the $4 million analysts had expected. Read More
Cephalon Inc., of Frazer, Pa., reported second quarter net sales of $730.1 million, a 2 percent increase over the second quarter of 2010, including $332.3 million for its central nervous system franchise, $140.6 million for its pain franchise and $158.8 million for its oncology franchise. Read More
NPS Pharmaceuticals Inc., of Bedminster, N.J., partnered with GlaxoSmithKline plc, of London, to develop two calcilytic compounds currently belonging to GSK. The compounds have relevance for rare disorders of calcium receptor activity, including hypocalcemia with hypercalciuria. Read More
Celgene Corp. will pay $25 million up front to Acceleron Pharma Inc. plus up to $217 million more in potential milestones, under a new collaboration agreement between the two companies for the development of an anemia therapeutic. Read More
AMAG Pharmaceuticals, Inc. shares (NASDAQ:AMAG) gained $1.61, or 11.2 percent, to close at $16 Wednesday following an unsolicited offer from New York-based hedge fund MSMB Capital Management to buy the Lexington, Mass.-based company's outstanding stock for $18 a share in cash, a 25 percent premium above the previous closing price, in a deal worth about $378 million. Read More
Trimel Pharmaceuticals Corp., of Toronto, said the FDA accepted its investigational new drug application for its bio-adhesive intranasal gel product development program, TBS-2. The company's TBS-2 product is being developed to treat the subset indication of the female sexual dysfunction anorgasmia. And IND was submitted in June. Read More
